Pfizer stock holds support as shares await fresh catalyst

Pfizer stock is supported by $63.64 billion in 2024 revenue and $8.0 billion in 2024 net income, while shares last closed at $23.86 on 17 July 2026.

Pfizer Inc. (US7170811035) is backed by $63.64 billion in 2024 revenue and $8.0 billion in 2024 net income, while the shares last closed at $23.86 on 17 July 2026. The latest annual report also showed adjusted diluted EPS of $3.11 for 2024, up from $2.38 in 2023, giving investors a clearer baseline for the stock.

2024 revenue at $63.64 billion

Pfizer reported $63.64 billion in revenue for 2024, compared with $58.50 billion in 2023, which means sales increased by $5.14 billion year over year. Net income rose to $8.0 billion in 2024 from $2.12 billion a year earlier, a change that highlights how much earnings recovered across the period.

Adjusted diluted EPS also improved to $3.11 in 2024 from $2.38 in 2023, according to the company’s annual reporting. That gives the stock a profit base that is better than the prior year, even if the market still tends to judge Pfizer by pipeline execution and post-pandemic normalization.

Profit recovery matters most

The margin picture improved with net income equal to roughly 12.6% of 2024 revenue, versus about 3.6% in 2023 using the same reported figures. For investors, that comparison is more useful than a single headline number because it shows the scale of the rebound.

Pfizer also ended 2024 with a much higher earnings profile than 2023, when the company was still working through a steep post-COVID reset. The year-over-year jump from $2.12 billion to $8.0 billion in net income is the most direct comparison in the latest annual results.

Shares closed at $23.86

Pfizer stock last closed at $23.86 on 17 July 2026, which gives the annual figures a live market anchor. That closing level sits far below the scale of the company’s 2024 revenue base, so the gap between operations and valuation remains visible.

The shares are still being priced against the durability of post-pandemic sales and the pace of new product growth. With 2024 revenue at $63.64 billion and net income at $8.0 billion, the stock trades on a business that is profitable again, but still in the middle of a longer reset.

Comirnaty remains relevant

Pfizer’s Comirnaty vaccine remains one of the company’s best-known products and a reference point for how the business can still monetize scale in infectious disease. The product helped define Pfizer’s recent earnings cycle, even as the company’s broader focus has shifted back toward oncology, immunology, and internal pipeline execution.

The product backdrop matters because Pfizer’s 2024 numbers were not driven by a single line item alone. Revenue of $63.64 billion and adjusted diluted EPS of $3.11 show that the business is now being measured on a wider earnings base than during the height of the vaccine era.

Price and scale

Pfizer stock closed at $23.86 on 17 July 2026, while the company’s 2024 revenue stood at $63.64 billion and net income at $8.0 billion. Those three figures frame the current debate around valuation, profit recovery, and the market’s patience with pipeline execution.

Pfizer Inc. remains a large-cap health care name listed on the New York Stock Exchange, and the latest annual figures show why the stock continues to attract attention even without a single dominant catalyst in the numbers. The valuation now reflects a company with a much stronger 2024 earnings base than 2023, but still one that depends on future product momentum.

Pfizer stock fact box

• Company: Pfizer Inc.
• ISIN: US7170811035
• Ticker: NYSE: PFE
• Trading venue: New York Stock Exchange
• Price (as of 17 July 2026, 16:00 ET): $23.86 USD
• Market capitalization: USD 136.0 billion (as of 17 July 2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500